The partnership with Finnish medical data sciences services vendor MedEngine will help BC Platforms offer end-to-end services for pharma and health-tech companies.
With this latest financing round, the Cambridge, UK-based developer of genomic data management software has raised a total of $3.2 million to date.
The institutions will develop a cloud-based storage and compute infrastructure for unrestricted and controlled-access data and metadata from NHGRI's projects.
CHOP's Gabriella Miller Kids First Pediatric Data Resource Center will use PhenoTips software from Gene42 to integrate "deep phenotyping" with genomic data.
Fueled by an NIH SBIR grant, analytics firm Cytobank is building out its machine-learning algorithms and adding pipelines to support big-picture research.
Finland-based Tieto and Swiss firm BC Platforms will jointly develop technology for integrating genomic and clinical data in the Northern European market.
British bioinformatics company Genestack hopes to overcome omics data fragmentation and inefficiencies in drug discovery with extensions to its NGS data platform.
The University of Nebraska Medical Center has created a SNOMED-CT and LOINC extension to make a cancer pathology report as "readily presentable as a CBC."
The company is hoping that consumers will use its platform to manage their health data, to participate in research, and to learn about their own and their family's health risks.
The DocUBuild tool grew out of the eMERGE network and helps institutions curate and manage genomic educational material for clinicians and patients alike.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.
New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.
The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.
In Nature this week: protein-coding variants associated with body-fat distribution, and more.